Lobbyists and activists are trying to slip unrelated measures into the coronavirus emergency bill. Congress should resist those pressures and keep the bill narrow and focused.
The FDA may eventually approve chloroquine, hydroxychloroquine, and other drugs currently used off‐label for the treatment of coronavirus and other viral infection. But clinicians are not prohibited from using them right now.
Policymakers looking for ways to mitigate the supply shock from the coronavirus outbreak should start with these regulatory reform proposals from Cato’s policy journal Regulation.
Predictably, the depths of the present economic crisis have led to several calls by economists for the Fed and other central banks to ready their money choppers for a major spending‐spree.
The COVID-19 outbreak is serious and scary, but it should not become an excuse to ignore costs relative to benefits when thinking about government policy.
